What they were paid
Nurix Therapeutics Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $101,458 | $0 | $157,509 | $1 | $258,968 |
| FY2024 | $95,437 | — | $276,179 | — | $371,616 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Nurix Therapeutics, Inc. DEF 14A filed March 27, 2026, accession 0001140361-26-011492, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Nurix Therapeutics pays directors a $50,000 cash retainer.
Committees
FY2025 · as the proxy prints themAudit · Nominating/Governance
The rest of the Nurix Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Anil Kapur | Independent Director | $217,926 |
| Arthur T. Sands | Director | $0 |
| David L. Lacey | Independent Director | $226,571 |
| Edward C. Saltzman | Independent Director | $220,218 |
| Judith A. Reinsdorf | Independent Director | $229,072 |
| Paul M. Silva | Independent Director | $230,322 |
| Roger Dansey | Independent Director | $421,684 |
| Roy D. Baynes | Independent Director | — |
The full Nurix Therapeutics compensation record
free company briefThis page is one director within Nurix Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat